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ABSTRACT
In this study, we aimed to investigate the protective effect 
of Vitamin U (Vit U) on amiodarone (AMD)-induced 
hepatotoxicity. Male Sprague-Dawley rats were randomly 
divided into four groups. Group I was control animals receiving 
corn oil for 7 days, Group II consisted of animals receiving Vit U 
(50 mg/kg) for 7 days, Group III consisted of animals receiving 
AMD (100 mg/kg) for 7 days and Group IV consisted of animals 
given AMD and Vit U (in same dose and time). AMD and Vit 
U were administered to rats by gavage. On the 8th day, all the 
animals fasted overnight were sacrificed. Blood and liver tissue 
samples were taken from animals. Serum total cholesterol 
levels and liver gamma glutamyl transferase (transpeptidase) 
adenosine deaminase and tissue factor activities, liver 
glycoprotein component level such as fucose, hexose and 
hexosamine were determined. All the parameters were found 
to be increased in AMD group as compared to control group. 
Administration of Vit U reversed these effects in AMD group. 
According to these results, we can conclude that Vit U can 
prevent AMD-induced liver injury. 
Keywords: Amiodarone, Glycoprotein, Liver, Tissue factor, 
Vitamin U
1. INTRODUCTION
Amiodarone (AMD) is a benzofuran derivative and shows 
class III antiarrhythmic drug profile. This drug has been 
widely used for treatment of ventricular and supraventricular 
tachyarrhythmias (1). AMD has a long half-life and a weak 
bioavailability (2) and tends to accumulate in many tissue 
and organs. Thus side effects and toxicities occur in parts 
of the body with this way. The most affected organs and 
tissues can be numbered as liver (3), lung (4), kidney (5), 
thyroid (6), brain (7) and ocular tissue (8). AMD is also 
reported as a hepatic mitochondrial toxicant that damages 
electron transport system by inhibiting complex I as well as 
b-oxidation of fatty acids. These pathways are carrying vital 
value for liver. Lewis et al. (9) and Simon et al. (10) reported 
AMD studies that have been carried out with human and 
they observed micro/macrovesicular steatosis in patients 
during experiments. In addition to that AMD has also a 
tendency to produce free radicals which can be associated 
with its toxicity (11,12). 
Glycoproteins, which are primarily known as hexose, 
hexosamine, fucose are important components of cell 
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membranes. They are composed of proteins which have 
carbohydrate moiety and this moiety is covalently bounded 
to their peptide side. The glycoproteins have many functions 
like mediating cell surface function, cell-cell recognition, 
cellular adhesion. The importance and increased levels of 
glycoproteins in various diseases have been reported as 
many researchers (13-15). The liver is a responsible organ for 
producing large amounts of glycoproteins present in blood 
(14). 
Vitamin U (Vit U) is a methionine derivative compound 
that is found in flowering plants (16) and in the species of 
Brassicaceae family (17). Although it has been called vitamin, 
it hasn’t been accepted into vitamin classification. Besides, 
this compound has many useful features like hypolipidemic 
(18), hepatoprotective (19) and gastroprotective effects (20) 
and wound-healing properties (21). 
In this study, we aimed to investigate protective effect of 
Vit U on glycoprotein content and enzyme activities on 
amiodarone induced liver injury.
2. MATERIAL AND METHODS
2.1. Material 
The experimental procedures were approved by the local 
Animal Care and Use Committee of Istanbul University, with 
the certification on the Application for the Use of Animals 
dated September 27, 2012 (approval ID: 2012 / 127). In this 
study, 3.5-4 months aged male Sprague-Dawley rats (Istanbul 
University Experimental Medical Research and Application 
Institute, DETAE) were used. Their diet consisted of standard 
animal pellet food and tap water ad libitum. Application of 
AMD dose and time were determined as Reasor et al. (22). 
Vit U dose were administered according to Sokmen et al. 
(19). A total of twenty nine rats were divided into 4 groups 
as follows. The groups include: Group I, control animals 
receiving corn oil for 7 days (n=6); Group II, animals 
receiving Vit U (50 mg/kg) for 7 days (n=7); Group III; 
animals receiving AMD (100 mg/kg) for 7 days (n=8); and 
Group IV, animals receiving Vit U (50 mg/kg) for 7 days 1 
h prior to the administration of AMD (100 mg/kg) (n=8). 
AMD and Vit U were administered to rats by gavage. On the 
8th day, all the animals fasted overnight were sacrificed.
Biochemical investigations were made in serum samples and 
liver tissues of all groups. Serum total cholesterol levels were 
determined according to Zlatkis et al. (23). The liver tissues 
were taken from animals under anesthesia. Tissue samples 
were washed with physiological saline (0.9% NaCl) and kept 
frozen until the day of the experiments. On the day of the 
experiments, liver samples were homogenized in cold 0.9% 
NaCl with a glass homogenizer to make up to a 10% (w/v) 
homogenate. The homogenates were centrifuged and the 
clear supernatant fraction was removed for biochemical 
analysis. In liver homogenates, gamma glutamyl transferase 
(transpeptidase) activity (g-GT) was measured by Szasz 
method (24), adenosine deaminase activity was determined 
according to Karker (25), tissue factor (TF) activity according 
to Quick’s one-stage method using normal plasma (26). 
Fucose levels of liver tissues were evaluated according to the 
method of Dische and Shettles (27) and hexose-hexosamine 
contents were estimated by the method by Winzler (28). The 
protein measurements in liver homogenates were determined 
according to Lowry et al. (29).
2.2. Statistical Analysis
Biochemical analysis was performed by one-way ANOVA 
followed by Duncan’s Newman-Keuls multiple comparison 
test. The values are expressed as the mean ± standart 
deviation (SD). P values less than 0.05 were considered to be 
significant.
3. RESULTS AND DISCUSSION
The serum total cholesterol levels and liver g-GT, ADA and 
TF activities were shown in Table 1. According to these 
results, the serum total cholesterol, liver g-GT, ADA and 
TF activities were found to be increased in AMD group as 
compared to control group in a significant manner (P < 0.05, 
P < 0.0001). Administration of Vit U reversed serum total 
cholesterol levels insignificantly while the reverse effect of vit 
U on g-GT, ADA and TF activity was in a significant manner 
in AMD group (P < 0.05, P < 0.0001). 
In Table 2, liver fucose, hexose and hexosamine levels 
were seen. All the glycoprotein levels were observed to be 
significantly increased in AMD group when compared to 
control group (P < 0.05). Vit U decreased all the component 
levels of liver in this table in a significant manner in AMD 
group (P < 0.05).
The liver is a vital organ where the basic metabolic pathways 
like carbohydrates, lipids and proteins as well as detoxification 
of xenobiotic substances occur. This situation brings it to be 
a target organ for toxicity. As being reported in literature 
by Seeff (30) and Jaeschke (31), drug induced liver injury 
becomes a big problem day by day. So finding new solutions 
to prevent drug induced liver injury become important. 
The liver has an importance for cholesterol and lipid 
metabolism. AMD is a phospholipase inhibitor and causes 
lipid accumulation in the liver. The studies that support this 
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idea especially associated with AMD hepatotoxicity have 
been published by many reporters (32-34). In parallel to this 
approach, we got elevated serum total cholesterol levels in 
AMD group according to the control group. Administration 
of Vit U decreased this level in AMD group. Seri et al. reported 
hypolipidemic effect of Vit U via helping the acceleration of 
lipid molecule excretion (35). We may suggest that Vit U 
reduced serum cholesterol levels via this way.
g-GT is an enzyme which catalyzes the breakdown of 
glutathione, using its gamma glutamyl part for transporting 
free amino acids across the membrane and into the cell 
(36). The importance of g-GT is being a marker enzyme for 
hepatic injury which is induced by drugs and this enzyme 
carries weight with in clinical practice. Some reporters have 
reported elevated g-GT activity levels in various either 
human hepatocyte culture studies induced by amiodarone 
or chemical-induced hepatotoxicity cases (37-39). Increased 
activity of this enzyme shows impairment for membrane 
integrity.  In our study, as parallel to these reports, we 
found elevated activity of g-GT in the AMD group as we 
compared to the control group. However, administration 
of Vit U reversed this activity in the AMD group. The 
decreased activities of this enzyme in this group may be due 
to membrane repair property of Vit U which was reported 
before by Racz et al (17). 
ADA is an important aminohydrolase in the purine 
metabolism which catalyzes deamination of either adenosine 
or deoxyadenosine to inosine or deoxyinosine. This reaction 
is one of the rate limiting steps in adenosine degradation 
(40). Increased activity of this enzyme indicates liver failure 
(41). In the present study, we got elevated ADA activity in 
AMD groups compared to control group. Vit U decreased 
this activity in AMD group. Elevated ADA activity may 
be associated with increased free radical levels caused 
by amiodarone. So we may suggest that Vit U showed its 
antioxidant activity by decreasing this enzyme activity in 
AMD group.
TF (tissue factor) is the principal cellular initiator of normal 
blood. It is a low molecular weight glycoprotein and a 
component of cell membrane. An increase in the activity of 
TF correlates with an increase in blood coagulation levels and 
a decrease in coagulation time. This elevated activity is also 
associated with alterations which occur in cell membrane 
due to either membrane composition or increased lipid 
peroxidation levels (42, 43). Increased TF activity has been 
Table 1. The serum total cholesterol levels, and the liver gamma glutamyl transferase (g-GT), adenosine deaminase (ADA) and 
tissue factor (TF) activities of control and experimental groups
Groups Total Cholesterol
(mg/dL)*
g-GT
(U/g protein)*
ADA
(U/g protein)*
TF
(second)*
Control 43.25 ± 8.68 19.97 ± 8.06 8.40 ± 1.29 207.60 ± 20.90
Control + Vit U 51.16 ± 8.24 23.52 ± 6.91 15.63 ± 6.08 181.30 ± 9.83a
Amiodarone 57.81 ± 9.36a 33.16 ± 4.77a 14.49 ± 1.64c 110.42 ± 10.56c
Amiodarone + Vit U 54.69 ± 4.32 24.59 ± 2.79b 9.57 ± 2.16b 210.81 ± 14.07d
*Mean ± SD
aP < 0.05 versus control group, bP < 0.05 versus amiodarone group, cP < 0.0001 versus control group, dP < 0.0001 versus amiodarone group.
Table 2. The liver fucose, hexose and hexosamine levels of control and experimental groups
Groups Fucose
(µg fucose/mg protein)*
Hexose
(mg glucose/mg protein)*
Hexosamine
(µg glucosamine/mg protein)*
Control 0.18 ± 0.05 0.26 ± 0.04 0.47 ± 0.15
Control + Vit U 0.22 ± 0.01 0.30 ± 0.01 0.26 ± 0.21
Amiodarone 0.50 ± 0.08a 0.41 ± 0.08a 1.14 ± 0.39a
Amiodarone + Vit U 0.24 ± 0.12b 0.25 ± 0.08b 0.19 ± 0.12b
*Mean ± SD
aP < 0.05 versus control group, bP < 0.05 versus amiodarone group
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reported in many diseases such as diabetes, hyperlipidemia, 
atherosclerosis and kidney diseases (44, 45). In our study, TF 
activity was significantly increased in the AMD group when 
compared to the control group. Vit U reversed this activity 
in AMD group. We may suggest this reducing effect can be 
associated with the protective effect of Vit U on membrane 
stability (17).
Glycoproteins are compounds that include carbohydrate 
moiety attached to peptide side of proteins. They are present 
in the extracellular matrix and believed to contribute to 
the structure of the matrix. They play an important role in 
tissue stabilization and are found as hormones, blood group 
substances (13, 46). Their levels are important for determining 
many diseases like tuberculosis (47), autoimmune thyroiditis 
(48), diabetes mellitus (49) and hepatotoxicity (50).  In the 
present study, we determined the glycoproteins like fucose, 
hexose and hexosamine levels of liver tissue. Levels of all the 
glycoproteins were found to be increased in the AMD group 
when compared to the control group. The elevation we have 
observed in the glycoprotein components of the AMD group 
may be a sign of a pathological process which results in the 
deposition of macromolecular components. This situation 
can be explained as cationic amphiphilic property of AMD. 
The hydrophobic ring structure and the hydrophilic side 
chain with a charged cationic amine group describe the nature 
of AMD. In addition to these properties, the halogen part of 
AMD enhances lipophilic character and provides to interact 
with membrane structure. So the membrane penetrability 
is affected by AMD. In a similar manner, administration of 
Vit U decreased these effects in the AMD group.  We may 
suggest that Vit U exerted a protective effect on glycoprotein 
structure of the liver tissue due to its  hypolipidemic effect 
which decreases lipid peroxidation levels, affecting the 
membrane stabilization.
4. CONCLUSION
This study shows that AMD induced hepatotoxicity can be 
prevented by Vit U, a methionine derivative substance. This 
protective effect of Vit U may be due to its antioxidant effect 
and membrane stabilizing property. In conclusion, we can 
suggest Vit U may be used on preventing AMD-induced 
hepatotoxicity.
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Vitamin U karaciğerde amiodaron toksisitesinin 
glikoprotein düzeyi, enzim ve doku faktör aktivitelerini 
iyileştirir
ÖZ
Bu çalışmada, amiodarone (AMD) ile oluşturulan 
hepatotoksisite üzerine U Vitamini (Vit U)’nin koruyucu etkisi 
araştırıldı. Erkek Sprague-Dawley sıçanlar rastgele dört gruba 
ayrıldı. Grup I; 7 gün boyunca mısır özü yağı verilen kontrol 
grubu, Grup 2; 7 gün boyunca Vit U (50 mg/kg) verilen 
hayvanlar, Grup III; 7 gün boyunca AMD (100 mg/kg) verilen 
hayvanlar ve Grup IV; aynı doz ve sürede AMD ve Vit U verilen 
hayvanlar. AMD ve Vit U sıçanlara gavaj yöntemiyle verildi. 
Sekizinci gün, bir gece aç bırakılan bütün hayvanlar sakrifiye 
edildi. Hayvanlardan kan ve karaciğer örnekleri alındı. Serum 
total kolesterol seviyeleri ile karaciğer gama glutamil transferaz, 
adenozin dezaminaz ve doku faktörü aktiviteleri, fukoz, heksoz 
ve heksozamin gibi karaciğer glikoprotein düzeyleri tayin edildi. 
Bu parametrelerin hepsi, kontrol grubu ile karşılaştırıldığında 
AMD grubunda artış olduğu  görüldü. Vit U verilmesi, AMD 
grubunda bu değerleri tersine çevirdi. Bu sonuçlara göre, 
AMD ile oluşturulan karaciğer hasarını U vitamininin önlediği 
sonucuna varabiliriz. 
Anahtar kelimeler: Amiodaron, Glikoprotein, Karaciğer, Doku 
Faktörü, Vitamin U
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